Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 14/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.57 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951287 | 1.00 | S1PR1 (0.61) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456676 | 1.00 | S1PR1 (0.61) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456542 | 0.88 | S1PR1 (0.58) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456832 | 0.88 | S1PR1 (0.58) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3457174 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456510 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456507 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456666 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456671 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3456285 | 0.87 | S1PR1 (0.59) | S1PR1S1PR5S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | claimed |
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258700-A1 | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | Pfizer Products Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR5 248/4885S1PR3 67/4885 |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR5 6/4885S1PR3 4/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR5 248/4885S1PR3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.